Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
VEGFA165 gene therapy ameliorates blood-labyrinth barrier breakdown and hearing loss
Jinhui Zhang, Zhiqiang Hou, Xiaohan Wang, Han Jiang, Lingling Neng, Yunpei Zhang, Qing Yu, George Burwood, Junha Song, Manfred Auer, Anders Fridberger, Michael Hoa, Xiaorui Shi
Jinhui Zhang, Zhiqiang Hou, Xiaohan Wang, Han Jiang, Lingling Neng, Yunpei Zhang, Qing Yu, George Burwood, Junha Song, Manfred Auer, Anders Fridberger, Michael Hoa, Xiaorui Shi
View: Text | PDF
Research Article Angiogenesis

VEGFA165 gene therapy ameliorates blood-labyrinth barrier breakdown and hearing loss

  • Text
  • PDF
Abstract

Millions of people are affected by hearing loss. Hearing loss is frequently caused by noise or aging and often associated with loss of pericytes. Pericytes populate the small vessels in the adult cochlea. However, their role in different types of hearing loss is largely unknown. Using an inducible and conditional pericyte depletion mouse model and noise-exposed mouse model, we show that loss of pericytes leads to marked changes in vascular structure, in turn leading to vascular degeneration and hearing loss. In vitro, using advanced tissue explants from pericyte fluorescence reporter models combined with exogenous donor pericytes, we show that pericytes, signaled by VEGF isoform A165 (VEGFA165), vigorously drive new vessel growth in both adult and neonatal mouse inner ear tissue. In vivo, the delivery of an adeno-associated virus serotype 1–mediated (AAV1–mediated) VEGFA165 viral vector to pericyte-depleted or noise-exposed animals prevented and regenerated lost pericytes, improved blood supply, and attenuated hearing loss. These studies provide the first clear-cut evidence that pericytes are critical for vascular regeneration, vascular stability, and hearing in adults. The restoration of vascular function in the damaged cochlea, including in noise-exposed animals, suggests that VEGFA165 gene therapy could be a new strategy for ameliorating vascular associated hearing disorders.

Authors

Jinhui Zhang, Zhiqiang Hou, Xiaohan Wang, Han Jiang, Lingling Neng, Yunpei Zhang, Qing Yu, George Burwood, Junha Song, Manfred Auer, Anders Fridberger, Michael Hoa, Xiaorui Shi

×

Figure 1

Loss of pericytes impairs vascular structure and function.

Options: View larger image (or click on image) Download as PowerPoint
Loss of pericytes impairs vascular structure and function.
(A) Schematic...
(A) Schematic of the transgenic Pdgfrb-CreERT2/iDTR mouse model incorporating an inducible Cre-loxP system. (B) The diagram shows the timeline of tamoxifen and diphtheria toxin (DT) administration and the time point for tissue harvest. (C) Colocalization of Cre and PDGFR-β signals (green) is seen in the strial vasculature of Pdgfrb-CreERT2/tdTomato mice (middle right and right: low-magnification and high-magnification images, n = 4). (D) Pericyte density in the strial vasculature is significantly reduced in pericyte-depleted mice (n = 7) compared with control mice (n = 6) at the apical, middle, and basal turn (****P < 0.0001 by Student’s t test). (E) Total vascular density in the stria is also significantly reduced in pericyte-depleted mice (****P < 0.0001 by Student’s t test). (F) Maximum and minimum vessel diameter in control and pericyte-depleted animals (maximum diameter is approximately 12.9 ± 1.8 μm in control mice (n = 6, total 153 vessels analyzed), 16.2 ± 2.6 μm in pericyte-depleted mice (n = 7, total 180 vessels analyzed); minimum vessel diameter is approximately 4.6 ± 1.1 μm in control mice, 1.9 ± 0.8 μm in pericyte-depleted mice. (G–I) Representative figures show the capillaries of the stria in control (G) and pericyte-depleted mice 2 weeks after DT injection (arrows, H and I). The depletion of pericytes leads to some vessel enlargement (arrows, H) and shrinkage (arrows, I). (J and K) Albumin-FITC leakage was identified under IVM in pericyte-depleted mice (white arrows, K) but not in the control animals (J). (L) Statistical difference in vascular leakage between control and pericyte-depleted animals (n = 3, ***P < 0.001 by Student’s t test). Data are presented as mean ± SEM. Scale bars: 10 μm (C left, middle left, middle right), 30 μm (C right). 20 μm (G, H, I). 50 μm (J, K).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts